: Drugmakers’ deal making will plow ahead despite antitrust scrutiny, analysts say
Read Time:5 Second
Big pharma goes shopping as “patent cliff” puts more than $225 billion in revenues at risk.
A reader needs to visualize his retirement buckets to be sure that he has enough.
Rocket Lab USA Inc.’s shares are soaring 12.1% Friday, boosted by KeyBanc Capital Markets’ price-target hike for the space-launch company.
Timing the market with the seasonal “Halloween Indicator.”
One year after the pause on student-loan payments ended, Uncle Sam is getting ready to tell credit-reporting companies which borrowers...
Nvidia’s stock is building a “pennant” chart pattern, which may suggest the preceding upturn is set to resume.
Smaller real-estate investors are worried about macroeconomic and political trends.